Journal Of Pharmaceutical Policy And Practice

SCIE

国际简称：J Pharm Policy Pract 参考译名：药品政策与实践杂志

主要研究方向：Health Professions-Pharmacy 非预警期刊审稿周期：14 Weeks

《药品政策与实践杂志》(Journal Of Pharmaceutical Policy And Practice)是一本由Springer Nature出版的以Health Professions-Pharmacy为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

3区中科院分区
Q2 JCR分区
133 年发文量
2.6 IF影响因子
未开放 是否OA
1 issue/year 出版周期
English 出版语言

The Journal of Pharmaceutical Policy and Practice is committed to promoting research, discussion, and application of pharmaceutical policies and practices worldwide to improve treatment outcomes and quality of life for patients. The main goal of the magazine is to provide a platform for professionals, scholars, policy makers, healthcare providers, and patients in the field of medicine to exchange and share the latest research results, policy analysis, and practical experience. The magazine covers a range of topics, including drug research and development, drug market access, drug pricing and reimbursement, drug procurement and supply, drug use and safety, drug policies and regulations, drug economic evaluation, drug information and education, drug quality management and regulation, etc.

[ 查看全部 ]

投稿咨询加急咨询

Journal Of Pharmaceutical Policy And Practice期刊信息

ISSN：2052-3211
出版语言：English
是否OA：未开放
出版地区：United Kingdom
是否预警：否
出版商：Springer Nature
出版周期：1 issue/year
开源占比：1
Gold OA文章占比：100.00%
OA被引用占比：1
出版国人文章占比：0
出版撤稿占比：
研究类文章占比：93.23%

Journal Of Pharmaceutical Policy And Practice CiteScore评价数据（2026年6月最新版）

CiteScore

SJR

SNIP

CiteScore 指数

4.4

0.74

1.186

学科类别	分区	排名	百分位
大类：Health Professions 小类：Pharmacy	Q1	5 / 52	91%
大类：Health Professions 小类：Health Policy	Q2	98 / 330	70%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Journal Of Pharmaceutical Policy And Practice中科院评价数据

《新锐期刊分区表》（2026年3月发布）

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	HEALTH POLICY & SERVICES 卫生政策与服务 PHARMACOLOGY & PHARMACY 药学	3区 3区

Journal Of Pharmaceutical Policy And Practice JCR评价数据

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：HEALTH POLICY & SERVICES	ESCI	Q2	49 / 125	61.2
学科：PHARMACOLOGY & PHARMACY	ESCI	Q3	195 / 356	45.4
学科：HEALTH POLICY & SERVICES	ESCI	Q3	64 / 125	49.2
学科：PHARMACOLOGY & PHARMACY	ESCI	Q2	143 / 356	59.97

Journal Of Pharmaceutical Policy And Practice历年数据统计

影响因子

中科院分区

Journal Of Pharmaceutical Policy And Practice中国学者发文选摘

1、Reconstructing the professional role of pharmacists in China from the perspective of public value theory: challenges and institutional pathway
Author: Han, Kexin; Wu, Shushan; Lin, Fanghui; Nie, Xiaoyan; Shi, Luwen; Guan, Xiaodong

Journal: JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE. 2026; Vol. 19, Issue 1, pp. -. DOI: 10.1080/20523211.2026.2654488
2、Effectiveness and safety of ceftazidime/avibactam versus polymyxin B in liver transplant recipients with carbapenem-resistant organism infections: a real-world cohort stud
Author: Zhang, Weiwei; Chen, Chuanlin; Li, Desheng; Zhou, Zhengdon; Sheng, Bo; Hu, Yongfang; Zhang, Zhenyu

Journal: JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE. 2026; Vol. 19, Issue 1, pp. -. DOI: 10.1080/20523211.2026.2641111
3、A real-world study based on the FAERS database evaluating adverse drug reactions in three amphotericin B lipid formulation
Author: Tong, Binliang; Wang, Jiaqi; Zhang, Yanjing; Liu, Yan; Wang, Jing; Duan, Liguang; Yan, Yuhang; Sun, Qixuan; Luan, Yueyao; Yu, Jing; Zhou, Chunhua

Journal: JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE. 2025; Vol. 18, Issue 1, pp. -. DOI: 10.1080/20523211.2025.2514155
4、Adverse events reporting of Etelcalcetide: a real-word analysis from FAERS databas
Author: Zhang, Dongdong; Cai, Ying; Sun, Yixin; Zeng, Peiji; Wang, Wei; Wang, Wenhui; Cai, Chengfu

Journal: JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE. 2025; Vol. 18, Issue 1, pp. -. DOI: 10.1080/20523211.2025.2479072
5、Home blood pressure during night-time sleep - a feasible treatment target for patients with hypertension: a proof-of-concept randomised controlled tria
Author: Lee, Eric Kam-Pui; Wang, Shuqi; Yip, Benjamin Hon-Kei; Yu, Esther Yee-Tak; Leung, Shuk-Yun; Han, Jinghao; Choi, Yue-Kwan; Chow, Kam-Fai; Chung, Wai-Ho; Yan, Byran P.; Mihailidou, Anastasia S.; McManus, Richard J.; Wong, Samuel Yeung-Shan

Journal: JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE. 2025; Vol. 18, Issue 1, pp. -. DOI: 10.1080/20523211.2025.2463435
6、Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 tria
Author: Ding, Yiling; Wang, Chunping; Shu, Yamin; Wang, Jinglin; Zhang, Qilin

Journal: JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE. 2025; Vol. 18, Issue 1, pp. -. DOI: 10.1080/20523211.2025.2464781
7、Relevance of perioperative fluid dynamics in liver transplantation to acute kidney injury and patient outcomes: a cross-sectional surve
Author: Li, Desheng; Guan, Qinghua; Chen, Chuanlin; Sheng, Bo; Zhang, Zhenyu; Hu, Yongfang

Journal: JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE. 2025; Vol. 18, Issue 1, pp. -. DOI: 10.1080/20523211.2024.2438225